Randomized, controlled trial of the effect of luseogliflozin in type 2 diabetic patients with fatty liver

Trial Profile

Randomized, controlled trial of the effect of luseogliflozin in type 2 diabetic patients with fatty liver

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Luseogliflozin (Primary) ; Metformin
  • Indications Fatty liver; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 Primary endpoint (A liver attenuation index at unenhanced CT 24 week after administration) has been met as per the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 03 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top